Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial.

ABSTRACT:

Background and aims

A 12-week placebo-controlled, sequential parallel Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT-2) trial evaluated the effects of extended-release injectable naltrexone plus extended-release oral bupropion (NTX + BUPN) on methamphetamine (MA) use over two stages. This study reports on the previously unpublished stage 2 MA use in participants randomized at stage 1 to receive NTX + BUPN through both stages compared with those assigned to placebo.

Design

This is a secondary analysis of the US National Institute on Drug Abuse (NIDA) ADAPT-2 network trial.

Setting

The parent ADAPT-2 trial was carried out across multiple NIDA Clinical Trials Network (CTN) sites in the United States.

Participants<

SUBMITTER: Li MJ 

PROVIDER: S-EPMC11436298 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature